Promega and Watchmaker Genomics Announce Strategic Partnership

Partnership to Advance Molecular Analysis with Next-Generation Reverse Transcriptase

15-Sep-2025 - Promega Corporation has entered a strategic partnership with Watchmaker Genomics to license a novel engineered reverse transcriptase. Designed for enhanced accuracy and sensitivity in RNA analysis, the enzyme will enhance Promega capabilities to manufacture and deliver both catalog and customized ...

Promega Corporation and FUJIFILM Cellular Dynamics Announce Strategic Collaboration to Advance Novel Assay Development

New licensing agreement will deliver luminescent reporter technology into iPSCs

14-Mar-2022 - Promega Corporation and FUJIFILM Cellular Dynamics, Inc. announced a strategic collaboration to advance novel assay development for drug discovery. Under a multi-year licensing agreement, FUJIFILM Cellular Dynamics will offer a wide range of custom differentiated iPSCs integrated with Promega ...

Merck Licenses Foundational CRISPR Integration Technology to Promega

23-Dec-2019 - Merck announced that it has signed a license agreement providing Promega Corp., a global life science manufacturer based in Madison, Wisconsin, USA access to Merck’s foundational CRISPR intellectual property. Promega will use Merck’s CRISPR genome-editing technology to create research products ...

Promega and BASF develop alternative method on identifying allergenic substances

REACH requires tests for skin sensitizing action

12-Apr-2013 - Promega and BASF have jointly developed an alternative method to animal studies that can reliably detect the allergenic potential of substances. Using a newly developed cell line, the reaction of skin cells to allergenic substances can now be demonstrated in the test tube. Allergic skin reactions ...

Horizon Discovery Announces Strategic Partnership with Promega to Develop Next-Generation Predictive Human Disease Models

09-Nov-2011 - Horizon Discovery Ltd. announced a strategic partnership agreement with Promega Corporation. The partnership centers on the delivery of endogenous gene reporting capabilities, in the form of Promega’s luciferase and HaloTag® reporter technologies, using Horizon’s proprietary homologous ...

Promega and Leica Microsystems Sign Agreement to Develop Fluorescent Ligands Enabling Live Cell Imaging at the Sub 100 nm Range

15-Aug-2008 - Promega Corp. announced that it has signed an agreement with Leica Microsystems to enable fluorescent imaging of proteins in live cells. Under the terms of the agreement, Promega will develop fluorescent ligands for its HaloTag fusion proteins, that will be used to label proteins within live ...

CyBio and Promega sign Collaboration Agreement for the Development of High-Throughput Applications

21-Jun-2007 - CyBio AG and Promega Corporation have signed a long-term collaboration agreement for the joint development and co-marketing of applications on CyBio's liquid handling instruments. CyBio maintains the co-operation with a partner who develops and distributes worldwide highly specific reagents, kits ...

Promega seeks to stop unlawful Benitec licensing activities of ddRNAi technology

12-Nov-2004 - To protect its exclusive licensing rights, Promega filed a motion to stop Benitec from further licensing activities of ddRNAi technology in the areas which have been granted exclusively to Promega. Filing with the United States District Court for the District of Delaware, the Promega motion ...

Caliper Life Sciences and Promega Introduce Validated Automation Protocols for Caliper's Sciclone Liquid Handling Workstations

25-Aug-2004 - Caliper Life Sciences, Inc., in collaboration with Promega Corporation, announced that it has integrated all of the Promega SV 96 Sample Preparation methods into its Caliper Sciclone ALH 3000 Workstation, including kits for genomic DNA purification, PCR clean-up, plasmid purification and RNA ...

Borean Pharma Appoints Dr. Johanna Holldack as Chief Operating Officer

Appointment reflects Borean Pharma`s progress towards the execution of its business strategy of partnering and licensing

10-Oct-2003 - Borean Pharma today announced the appointment of Johanna Holldack, M.D., as Chief Operating Officer. With more than 13 years of experience in the pharmaceutical and biotech industries, Dr. Holldack has been responsible for the development and approval of products both in the U.S. and Europe. In ...